Synergy suffers from constipation of cash?

Very good news came for Synergy pharmaceuticals, the FDA approved expanded indication to treat irritable bowel for one of their products.
  However, according to some analysts seems that the company suffers from cash constipation (lol) which limits its access to loans with which it could exploit this product to the maximum.

I think it is quite interesting what can happen with this company in the next few days, I will be pending how it develops, obviously everything will depend on the level of certainty that may generate in investors, words like cash, loans and strategies will be key.
評論: Nop, not good.
ZH 繁體中文
EN English
EN English (UK)
EN English (IN)
DE Deutsch
FR Français
ES Español
IT Italiano
PL Polski
SV Svenska
TR Türkçe
RU Русский
PT Português
ID Bahasa Indonesia
MS Bahasa Melayu
TH ภาษาไทย
VI Tiếng Việt
JA 日本語
KO 한국어
ZH 简体中文
AR العربية
HE עברית
首頁 股票篩選器 外匯篩選器 加密貨幣篩選器 全球財經日曆 如何運作 圖表功能 網站規則 版主 網站 & 經紀商解決方案 小工具 圖表庫 功能請求 部落格 & 新聞 常見問題 幫助 & 維基 推特
個人資料 個人資料設定 帳戶和帳單 我的客服工單 聯絡客服 發表的想法 粉絲 正在關注 私人訊息 在線聊天 登出